Hope Hicks won’t likely be the last one out the door of this White House. And according to political consultant Rick Wilson, President Trump’s son-in-law and senior advisor Jared Kushner will be next.
“I don’t think there’s a tenable path for Jared Kushner to stay in the White House. That’s just because he’s under multiple investigations from state and federal law enforcement and regulatory agencies,” said Wilson.
“I think he’s pretty much a dead man walking at this point.”
Wilson pointed to rumors the President wants Chief of Staff John Kelly to get rid of both Kushner and Ivanka Trump.
Kushner at one point had clearance for classified information and unfettered access to the President. In the past few weeks, though, he had his security privileges stripped, and now it seems as though he has one foot out the door.
Speculation is also swirling about the exit of Gary Cohn, Trump’s top economic adviser. The former Goldman Sachs COO voiced strong opposition to the President’s proposed steel and aluminium tariffs.
But Wilson thinks Cohn might stick it out for a little longer. According to one of Wilson’s sources, Cohn “wants to help do a banking deal with the Senate.” Wilson didn’t have further details about the deal.
A new poll finds most U.S. adults are worried about health care becoming more expensive.
The White House budget office says mass firings of federal workers have started in an attempt to exert more pressure on Democratic lawmakers as the government shutdown continues.
President Donald Trump says “there seems to be no reason” to meet with Chinese leader Xi Jinping as part of an upcoming trip to South Korea after China restricted exports of rare earths needed for American industry. The Republican president suggested Friday he was looking at a “massive increase” of import taxes on Chinese products in response to Xi’s moves. Trump says one of the policies the U.S. is calculating is "a massive increase of Tariffs on Chinese products coming into the United States." A monthslong calm on Wall Street was shattered, with U.S. stocks falling on the news. The Chinese Embassy in Washington hasn't responded to an Associated Press request for comment.
Most members of the Federal Reserve’s interest-rate setting committee supported further reductions to its key interest rate this year, minutes from last month’s meeting showed.
From Wall Street trading floors to the Federal Reserve to economists sipping coffee in their home offices, the first Friday morning of the month typically brings a quiet hush around 8:30 a.m. eastern, as everyone awaits the Labor Department’s monthly jobs report.
The Supreme Court is allowing Lisa Cook to remain as a Federal Reserve governor for now.
Rep. John Moolenaar has requested an urgent briefing from the White House after Trump supported a deal giving Americans a majority stake in TikTok.
A new report finds the Department of Government Efficiency’s remaking of the federal workforce has battered the Washington job market and put more households in the metropolitan area in financial distress.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
